➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Merck
Mallinckrodt
Medtronic

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

XALATAN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Xalatan, and what generic alternatives are available?

Xalatan is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xalatan

A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.

  Free Forever Trial

Drug patent expirations by year for XALATAN
Drug Prices for XALATAN

See drug prices for XALATAN

Drug Sales Revenue Trends for XALATAN

See drug sales revenues for XALATAN

Recent Clinical Trials for XALATAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Icahn School of Medicine at Mount SinaiPhase 4
Samil Pharmaceutical Co., Ltd.Phase 4
CHA UniversityPhase 4

See all XALATAN clinical trials

Pharmacology for XALATAN
Paragraph IV (Patent) Challenges for XALATAN
Tradename Dosage Ingredient NDA Submissiondate
XALATAN SOLUTION/DROPS;OPHTHALMIC latanoprost 020597

US Patents and Regulatory Information for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 AT RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for XALATAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3461484 2021C/515 Belgium ⤷  Free Forever Trial PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
0364417 97C0111 Belgium ⤷  Free Forever Trial PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
0364417 97C0128 France ⤷  Free Forever Trial PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
0364417 9690031-1 Sweden ⤷  Free Forever Trial PRODUCT NAME: LATANOPROST
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.